ArticleBMC cancer2020

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.

Serenella Eppenberger-Castori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.